Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,780.39
(
-0.07%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.43
(
-2.02%
)
Bitcoin
70,196.40
(
-1.47%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197737

Monday, 03/06/2017 5:33:34 PM

Monday, March 06, 2017 5:33:34 PM

Post# of 257262
(MNTA)—UK Court invalidates ABBV’s Humira “use” patents on three indications:

http://www.cnbc.com/2017/03/05/uk-court-delivers-high-stakes-decision-on-worlds-best-selling-drug.html

The ruling determined that AbbVie's indications pertaining to rheumatoid arthritis, psoriasis and psoriatic arthritis were unpatentable.

Although today’s UK judgment not affect the enforceability of ABBV’s US patents, I expect a similar outcome when ABBV’s US method of use patents for Humira are tested in court, as noted in #msg-118781959.

The plaintiff in the UK lawsuit was Samsung Bioepis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now